Latest Contracts News

Hejaz High Income Active ETF delivered a 3.74% net return for the year, well below its reported 13.93% benchmark return. Net assets rose sharply to $9.64 million, but the increase was driven mainly by new applications rather than investment performance.

KGL Resources says its Jervois copper project is funded through construction and ramp-up after a US$300 million Wheaton agreement and a post-year-end A$300 million equity raising. The company is now targeting a final investment decision in the second half of 2026 and first copper concentrate in 2028, while its annual report highlights the execution risks still attached to that timetable.

Coolabah Active Global Bond Fund delivered net returns of up to 6.20% in the year to 30 June 2026, ahead of its global bond benchmark. The fund also added an ASX-traded ETF class shortly before year-end, while using repurchase agreements and derivatives as part of its strategy.

Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.

Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.

Walter Scott Global Equity Fund’s operating profit fell to A$4.1 million in 2026 from A$349.5 million, while net assets dropped by about A$1.1 billion. The audited report points to weaker investment gains and substantial redemptions, although the fund remained fully invested in quoted equities and received an unmodified audit opinion.

Macquarie Income Opportunities Fund reported a sharp decline in operating profit for 2026 as fair-value gains weakened, despite growth in net assets and distributions. The audited fund ended the year with A$3.033 billion attributable to unitholders and an unqualified audit opinion.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

6K Additive has signed a 30-month Nickel 718 powder supply agreement with US advanced manufacturer ADDMAN, carrying a stated value of up to US$10.8 million. The deal also introduces a buy-back arrangement for used powder, linking new sales with recycled feedstock.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.

PDI Gold’s first full annual report after its Robex merger shows a transformed West African gold business with US$193.7 million in cash and two producing mines. The statutory result remains a US$63.7 million loss, while Bankan’s next phase still depends on an exploitation permit from Guinea.